Prolonged bleeding time and lupus anticoagulant: A second paradox in the antiphospholipid syndrome

Arthritis and Rheumatism

Volumn 50, Issue 11, 2004, Pages 3605-3609

  Urbanus, R T ^a   De Laat, H B ^a   De Groot, P G ^a   Derksen, R H W M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LUPUS ANTICOAGULANT; VON WILLEBRAND FACTOR;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLEEDING TIME; CLINICAL ARTICLE; FEMALE; HEMOSTASIS; HUMAN; KIDNEY BIOPSY; PERCUTANEOUS BIOPSY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE FUNCTION; THROMBOSIS; TIME; TREATMENT CONTRAINDICATION;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BLEEDING TIME; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; MIDDLE AGED; PLATELET COUNT; PLATELET FUNCTION TESTS; VON WILLEBRAND FACTOR;

EID: 8444235999     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20586     Document Type: Article

References (15)

1. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
2. Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus: comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996;76:916-24.
3. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al, for the Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27.
4. Nochy D, Daugas E, Droz D, Beaufils H, Grunfeld JP, Piette JC, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 1999;10:507-18.
5. Daugas E, Nochy D, Huong du LT, Duhaut P, Beaufils H, Caudwell V, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 2002;13:42-52.
6. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
7. Van der Plas RM, Gomes L, Marquart JA, Vink T, Meijers JC, de Groot PG, et al. Binding of von Willebrand factor to collagen type III: role of specific amino acids in the collagen binding domain of vWF and effects of neighboring domains. Thromb Haemost 2000;84:1005-11,
8. Lawrie AS, Hoser MJ, Savidge GF. Phast assessment of vWf:Ag multimeric distribution. Thromb Res 1990;59:369-73.
9. Macchi L, Rispal P, Clofent-Sanchez G, Pellegrin JL, Nurden P, Leng B, et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol 1997;98:336-41.
10. Harker LA, Slichter SJ. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972;287:155-9.
11. Orlando E, Cortelazzo S, Marchetti M, Sanfratello R, Barbui T. Prolonged bleeding time in patients with lupus anticoagulant. Thromb Haemost 1992;68:495-9.
12. Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, de Groot PG. Dimers of β2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003;278:33831-8.
13. Oosting JD, Derksen RH, Blokzijl L, Sixma JJ, de Groot PG. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity - studies in a thrombosis model. Thromb Haemost 1992;68:278-84.
14. Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001;89:273-93.
15. Aiello S, Noris M, Remuzzi G. Nitric oxide/L-arginine in uremia. Miner Electrolyte Metab 1999;25:384-90.